In other cancers, IL-21 blockade was able to drastically reduce B cell activation induced by co-administration of anti-PD-1 and anti-CTLA-4 therapy, highlighting the importance of Tfh cell-secreted effector molecules in cancer immunotherapy [55]. This evidence concerns the gene IL21 and cancer.